Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action-Reference-Cited by-同舟云学术

Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action

Published:2011-04 Issue:2 Volume:13 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

DeFazio-Eli Lisa,Strommen Kristi,Dao-Pick Trang,Parry Gordon,Goodman Laurie,Winslow John

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr2866.pdf

Reference73 articles.

1. Cochet C, Kashles O, Chambaz EM, Borrello I, King CR, Schlessinger J: Demonstration of epidermal growth factor-induced receptor dimerization in living cells using a chemical covalent cross-linking agent. J Biol Chem. 1988, 263: 3290-3295.

2. Heldin CH: Dimerization of cell surface receptors in signal transduction. Cell. 1995, 80: 213-223. 10.1016/0092-8674(95)90404-2.

3. Greenfield C, Hiles I, Waterfield MD, Federwisch M, Wollmer A, Blundell TL, McDonald N: Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J. 1989, 8: 4115-4123.

4. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991, 251: 936-939. 10.1126/science.1840698.

5. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, Folkman J: Betacellulin: a mitogen from pancreatic beta cell tumors. Science. 1993, 259: 1604-1607. 10.1126/science.8456283.

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay;Modern Pathology;2024-09

2. Dual‐Targeting of the HER2 Cancer Receptor with an Antibody‐Directed Enzyme and a Nanobody‐Guided MMAE Prodrug Scaffold;ChemBioChem;2024-08-20

3. Disrupting EGFR–HER2 Transactivation by Pertuzumab in HER2-Positive Cancer: Quantitative Analysis Reveals EGFR Signal Input as Potential Predictor of Therapeutic Outcome;International Journal of Molecular Sciences;2024-05-29

4. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion;International Journal of Molecular Sciences;2024-04-11

5. Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities;Acta Pharmacologica Sinica;2024-02-15